GCM
KALV

Graham Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

Graham Capital Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,479
Closed -$88.8K – 1400
2024
Q4 		$88.8K Buy
+10,479
New +$109K ﹤0.01% 1168

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Graham Capital Management's KALV Position: Q1 2025 in Review

Graham Capital Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2025, closing a stake of 10,479 shares — an estimated $88.8K sold.

Graham Capital Management first reported a position in KALV in Q4 2024 and held it in 1 quarter. The position peaked at $88.8K in Q4 2024. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2025.

  • Graham Capital Management reported no remaining KalVista Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Graham Capital Management sold 10,479 KalVista Pharmaceuticals shares in Q1 2025, an estimated $88.8K.
  • Graham Capital Management first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Graham Capital Management's KalVista Pharmaceuticals position peaked at $88.8K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2025.

Based on Graham Capital Management's 13F filing for Q1 2025, filed 15 May 2025.